Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: Results from the multicenter, phase 2 REMORA trial
Thymic carcinoma is a cancer of the thymus epithelium with a poor prognosis, and is both biologically and pathologically distinct from thymoma [1,2]. The disease has an incidence of approximately 0.03 per 100,000 people per year, meeting the definition of a rare cancer [3 –5]. The Japanese Society of Thoracic Surgery reported that thymic carcinoma accounted for 0.3 % of lung cancer surgeries in 2008 [6]. (Source: Lung Cancer)
Source: Lung Cancer - March 30, 2024 Category: Cancer & Oncology Authors: Seiji Niho, Jun Sato, Miyako Satouchi, Shoichi Itoh, Yusuke Okuma, Hidenori Mizugaki, Haruyasu Murakami, Yasuhito Fujisaka, Toshiyuki Kozuki, Kenichi Nakamura, Ryunosuke Machida, Yuichiro Ohe, Toshiyuki Tamai, Hiroki Ikezawa, Noboru Yamamoto Source Type: research
Spatiotemporal distribution of mediastinal neoplasms: A comprehensive multi-center study
The widespread utilization of chest computed tomography (CT) imaging [1] and the implementation of lung cancer screening projects [2] have led to a heightened detection rate of mediastinal lesions in recent years [3,4]. Mediastinal neoplasms are typical thoracic disease, with a prevalence of 0.77 %–1.68 %, affecting up to 60–130 million individuals worldwide [3,5,6]. These lesions encompass a variety of benign and malignant diseases, and the available treatment options are closely tied to their classification [7]. (Source: Lung Cancer)
Source: Lung Cancer - March 30, 2024 Category: Cancer & Oncology Authors: Yu Jiang, Yuechun Lin, Chao Yang, Ping He, Zhichao Liu, Haixuan Wang, Ran Zhong, Linchong Huang, Zhigang Li, Fuhao Xu, Xu Lin, Jun Liu, Xin Xu, Shuben Li, Fei Cui, Wei Wang, Wenhua Liang, Lei Zhao, Jian Hu, Bin Li, Donglai Chen, Wenfang Tang, Chun Chen, J Source Type: research
Familial rare EGFR-mutant lung cancer syndrome: Review of literature and description of R776H family
Interest in hereditary lung cancer is increasing, in particular germline mutations in the Epidermal Growth Factor Receptor (EGFR) gene. We review the current literature on this topic, discuss risk of developing lung cancer, treatment and screening options and describe a family of 3 sisters with lung cancer and their unaffected mother all with a rare EGFR germline mutation (EGFR p.R776H). (Source: Lung Cancer)
Source: Lung Cancer - March 29, 2024 Category: Cancer & Oncology Authors: L. Gabriel, T. McVeigh, S. Macmahon, Z. Avila, L. Donovan, I. Hunt, A. Draper, A. Minchom, S. Popat, M. Davidson, J. Bhosle, C. Milner Watts, M. Hubank, L. Yuan, MER O'Brien Source Type: research
Lung cancer among the Elderly in Denmark – A comprehensive population-based cohort study
The prognosis for lung cancer patients remains dire, representing the predominant cause of cancer-related mortality worldwide [1]. In Denmark, fast-track cancer patient pathways (CPPs) have been implemented in order to ensure a swift diagnostic work-up and referral to treatment with minimal delay [2]. Furthermore, notable advancement in treatment have been achieved for both limited-stage and for advanced-stage disease [3 –5]. These treatment advances have resulted in an improved prognosis for lung cancer patients in Denmark. (Source: Lung Cancer)
Source: Lung Cancer - March 29, 2024 Category: Cancer & Oncology Authors: Niels Lyhne Christensen, Anja Gouliaev, Sean McPhail, Georgios Lyratzopoulos, Torben Riis Rasmussen, Henry Jensen Tags: Research Paper Source Type: research
Establishing mesothelioma patient-derived organoid models from malignant pleural effusions
Pleural mesothelioma is an aggressive cancer arising in the mesothelial cells that line the lungs and the chest wall. Mesothelioma is characterized by mutations in tumor suppressor genes, including cyclin-dependent kinase inhibitor 2A (CDKN2A) and BRAC1-associated protein (BAP1), that, at present, are difficult to target therapeutically [1]. First-line treatment for unresectable mesothelioma is combination chemotherapy of cisplatin plus pemetrexed. Unfortunately, approximately 60 % of mesothelioma patients do not respond significantly to chemotherapy, and those that do eventually become resistant [2]. (Source: Lung Cancer)
Source: Lung Cancer - March 27, 2024 Category: Cancer & Oncology Authors: Ashleigh J. Hocking, Lauren A. Mortimer, Alexandra L. Farrall, Prudence A. Russell, Sonja Klebe Source Type: research
Malate, a natural inhibitor of 6PGD, improves the efficacy of chemotherapy in lung cancer
The importance of cellular metabolic reprogramming in cancer has attracted considerable attention in recent years [1]. Accumulating evidence indicates that tumor-associated genes [2], cellular microenvironment [3,4], transcription factors [5], and non-coding RNAs [6], as well as mutations in metabolic enzymes themselves or changes in the activity of protein metabolic regulators [7,8], can lead to metabolic reprogramming of tumor cells. Many study have described energy reprogramming events as a cancer hallmark that enable cancer cells to survive, suggesting that metabolic enzymes are attractive molecular targets for the dev...
Source: Lung Cancer - March 23, 2024 Category: Cancer & Oncology Authors: Mingming Sun, Qi Feng, Qi Yan, Huifang Zhao, Haiyan Wang, Shuai Zhang, Changliang Shan, Shuangping Liu, Jiyan Wang, Hongyan Zhai Source Type: research
Osimertinib plus local treatment for brain metastases versus osimertinib alone in patients with EGFR-Mutant Non-Small Cell Lung Cancer
Lung cancer is the leading cause of cancer death worldwide. Non-small cell lung cancer (NSCLC) accounts for approximately 85 % of all lung cancer cases [1]. Approximately 20–40 % of patients with lung cancer have brain metastases (BMs) at diagnosis or during their disease course [2,3]. The overall survival (OS) of patients with BMs is poor [4]. BMs worsen patients’ quality of life more than other metastases such as bone and liver metastases [5]. The risk of BMs is higher in epidermal growth factor receptor (EGFR)-mutant NSCLC than in EGFR wild-type NSCLC [6]. (Source: Lung Cancer)
Source: Lung Cancer - March 22, 2024 Category: Cancer & Oncology Authors: Takehiro Tozuka, Rintaro Noro, Hideaki Mizutani, Futoshi Kurimoto, Taiki Hakozaki, Kakeru Hisakane, Tomoyuki Naito, Satoshi Takahashi, Namiko Taniuchi, Chika Yajima, Yukio Hosomi, Takashi Hirose, Yuji Minegishi, Tetsuya Okano, Koichiro Kamio, Tomoyoshi Ya Source Type: research
On the Hispanic paradox in lung cancer
We have read with interest Arrieta et al. ’s publication [1], reporting on the mutation profiles of Hispanic NSCLC that were consecutively treated at the thoracic oncology unit of the National Cancer Institute, Mexico, between 2007 and 2014. The results indicate that among 1260 patients, 340 had EGFR mutation (27 %). In a previous study , 2012 Arrieta et al. [2] reported the results from years 2007–2010 on 914 patients. Though possible, it is pretty odd that 914 were treated from 2007 to 2010, but in the following 4-year period, the added number of patients was only 346 (for a total of 1260). (Source: Lung Cancer)
Source: Lung Cancer - March 20, 2024 Category: Cancer & Oncology Authors: John Rodriguez Source Type: research
Revisiting the lung cancer screening eligibility criteria to promote equity for Black individuals
Lung cancer is the leading cause of cancer death in the United States (U.S) in men and women accounting for about 25 % of all cancer mortality [1–3]. Black individuals are disproportionately affected by lung cancer compared with all other racial/ethnic groups in the U.S [4,5]. Black individuals smoke fewer cigarettes [6,7] and start smoking later in life [8,9], yet they are at greater risk of developing lung cancer than Whites [10] even after controlling for socioeconomic status and other risk factors [10–12]. (Source: Lung Cancer)
Source: Lung Cancer - March 19, 2024 Category: Cancer & Oncology Authors: Abdi T. Gudina, Charles Kamen, Sara J. Hardy, Lee Kehoe, Eva Culakova, Ana-Paula Cupertino Source Type: research
Anlotinib plus docetaxel vs. docetaxel alone for advanced non-small-cell lung cancer patients who failed first-line treatment: A multicenter, randomized phase II trial
Non-small-cell lung cancer (NSCLC) represents the predominant form (85 %-90 %) of malignant lung neoplasms [1]. In 2020, lung cancer accounted for 2,206,771 new cases globally, leading to 1,796,144 fatalities [2,3]. At the dawn of the 21st century, chemotherapy remained the cornerstone of NSCLC treatment. However, the emergence of immunotherapy has introduced a pl ethora of innovative strategies for NSCLC management [4,5]. Currently, platinum-based chemotherapy, either alone or in combination with immunotherapy, is the endorsed first-line treatment paradigm for NSCLC [1,6,7]. (Source: Lung Cancer)
Source: Lung Cancer - March 18, 2024 Category: Cancer & Oncology Authors: Xingxiang Pu, Zemin Xiao, Jia Li, Zhijun Wu, Zhongxia Ma, Jie Weng, Maoliang Xiao, Yanhua Chen, Yongqing Cao, Peiguo Cao, Qianzhi Wang, Yan Xu, Kang Li, Bolin Chen, Fang Xu, Liyu Liu, Yi Kong, Hui Zhang, Huaxin Duan, Lin Wu Tags: Research Paper Source Type: research
A pragmatic guide for management of adverse events associated with lorlatinib
Anaplastic lymphoma kinase (ALK) gene rearrangements are present in 2 % to 7 % of the non-small cell lung cancer (NSCLC) patient population [1–3]. Identification of ALK gene rearrangements in NSCLC is clinically important as tumors harboring this genomic alteration are highly sensitive to ALK tyrosine kinase inhibitors (TKIs) [3]. According to international gui delines, the preferred first-line treatment option for patients with ALK-positive metastatic NSCLC includes second-generation ALK TKIs, alectinib or brigatinib, or the third-generation ALK TKI, lorlatinib [4,5]. (Source: Lung Cancer)
Source: Lung Cancer - March 14, 2024 Category: Cancer & Oncology Authors: Geoffrey Liu, Julien Mazieres, Jan Stratmann, Sai-Hong Ignatius Ou, Tony Mok, Mary Grizzard, Yasushi Goto, Enriqueta Felip, Benjamin J. Solomon, Todd M. Bauer Tags: Review article Source Type: research
Ex vivo drug testing of patient-derived lung organoids to predict treatment responses for personalized medicine
Lung cancer remains the leading cause of cancer-related mortality worldwide accounting for approximately 1.8 million deaths in 2020 [1]. Non-small cell lung cancer (NSCLC) is the predominant histologic subtype, accounting for 85 % of all lung cancer cases in the United States [2]. In comparison, small cell lung cancer (SCLC) represents 15 % of lung cancer cases, occurs almost exclusively in smokers and has the most aggressive clinical course with survival outcomes of 2 to 4 months in untreated patients [3,4]. (Source: Lung Cancer)
Source: Lung Cancer - March 13, 2024 Category: Cancer & Oncology Authors: Josephine A. Taverna, Chia-Nung Hung, Madison Williams, Ryan Williams, Meizhen Chen, Samaneh Kamali, Vaishnavi Sambandam, Cheryl Hsiang-Ling Chiu, Pawel A. Osmulski, Maria E. Gaczynska, Daniel T. DeArmond, Christine Gaspard, Maria Mancini, Meena Kusi, Abh Tags: Review article Source Type: research
Survival benefit in EGFR-wild and ALK negative NSCLC patients who participate in clinical trials compared to standard-of-care: Propensity-matched analysis
Over the past two decades, remarkable progress has been made in therapeutic applications for non-small-cell lung cancer (NSCLC), with fundamental knowledge of tumor biology and drug development. Notably, spectacular advances in the management of NSCLC have been accomplished in clinical trials. (Source: Lung Cancer)
Source: Lung Cancer - March 12, 2024 Category: Cancer & Oncology Authors: Hyun-Ae Jung, Boram Park, Sehhoon Park, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn Tags: Research Paper Source Type: research
Comment on: Frozen sections accurately predict the IASLC proposed grading system and prognosis in patients with invasive lung adenocarcinomas
We recently have read with great interest an article published in Lung Cancer (Feb 17, 2023) by Fan et al. entitled: Frozen sections accurately predict the IASLC proposed grading system and prognosis in patients with invasive lung adenocarcinomas [1]. Their study provides valuable insights into the accuracy and interobserver agreement of the International Association for the Study of Lung Cancer (IASLC) grading system on frozen section (FS) and its prognostic value. In the research, three pathologists reviewed FS and final pathology (FP) slides from 373 stage I lung adenocarcinomas (ADC) cases (retrospective) and 212 cases...
Source: Lung Cancer - March 11, 2024 Category: Cancer & Oncology Authors: Tianfei Yu, Xue Zhou, Ming Li Source Type: research
The impact of pre-treatment smoking status on survival after chemoradiotherapy for locally advanced non-small-cell lung cancer
The causal relationship between tobacco use and lung cancer has long been known [1,2]. As well as providing conclusive evidence of this link, the British doctors study also clearly identified higher mortality rates for smokers and a survival benefit associated with smoking cessation [3]. This is applicable to the general population and provides the rationale for public health measures to lower smoking rates. However, the impact of smoking status on outcomes after a lung cancer diagnosis is less clearly defined. (Source: Lung Cancer)
Source: Lung Cancer - March 10, 2024 Category: Cancer & Oncology Authors: Neil D. Wallace, Marliese Alexander, Jing Xie, David Ball, Fiona Hegi-Johnson, Nikki Plumridge, Shankar Siva, Mark Shaw, Susan Harden, Tom John, Ben Solomon, Ann Officer, Michael MacManus Tags: Research Paper Source Type: research
